DISC MEDICINE INC. -

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

09 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

20 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

11 Dec 2023 19:30:00 By Nasdaq GlobeNewswire

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

11 Dec 2023 11:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

14 Nov 2023 15:44:17 By Nasdaq GlobeNewswire

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

08 Nov 2023 15:30:11 By Nasdaq GlobeNewswire

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

23 Oct 2023 08:15:00 By Nasdaq GlobeNewswire

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

03 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

20 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

30 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

11 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

27 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

22 Jun 2023 15:15:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

13 Jun 2023 21:39:30 By Nasdaq GlobeNewswire

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 Jun 2023 15:00:00 By Nasdaq GlobeNewswire

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

09 Jun 2023 06:00:00 By Nasdaq GlobeNewswire